Time Savings with Trastuzumab Subcutaneous (SC) Injection vs. Trastuzumab Intravenous (IV) Infusion: a Time and Motion Study in 3 Russian Centers

 

Time Savings with Trastuzumab Subcutaneous (SC) Injection vs. Trastuzumab Intravenous (IV) Infusion: a Time and Motion Study in 3 Russian Centers

Time and Motion (T&M) studies are observational non-interventional studies to quantify efficiency-related outcomes.In Russia, trastuzumab (Herceptin®) is approved, among other indications, for the treatment of patients with HER2-positive Early Breast Cancer (EBC). A new subcutaneous (SC) formulation has been developed to be administered via a Single-use Injection Device (SID) and Hand-Held Syringe (HHS). Intravenous infusion (IV) of trastuzumab usually takes 30–90 minutes,2 whereas trastuzumab SC is administered in less than 5 minutes. We previously showed that SC trastuzumab led to a 21%–51% reduction in the “active” healthcare professional's (HCP) time, and a 58%–79% reduction in patient time in the infusion chair compared to IV trastuzumab
Time Savings with Trastuzumab Subcutaneous (SC) Injection vs. Trastuzumab Intravenous (IV) Infusion: a Time and Motion Study in 3 Russian Centers